Education

• Postdoctoral Fellow: Department of Pharmacology & Moores Cancer Center University of California San Diego (PI: Kun-Liang Guan)
• Postdoctoral Fellow: Department of Pharmacology, Yonsei University College of Medicine, Seoul (PI: Min Goo Lee)
• Department of Pharmacology: Yonsei University College of Medicine, Seoul (PI: Min Goo Lee)
• Department of Pharmacology: Yonsei University College of Medicine, Seoul (PI: Min Goo Lee)
• B.S.,: Department of Biology, Yonsei University, Seoul (PI: Woo Taek Kim)

Professional Experience

• 2016-present Professor, Department of Biochemistry, Yonsei University
• 2026-present Director, METAZERO Initiative Research Center
• 2024-present Director, Metastatic Plasticity Research Center
• 2020-2024 Director, AST Metastasis Research Center
• 2018-2023 Fellow, Suh Kyungbae Foundation

Honors and Awards

• 2025 Blue Ribbon Award, Korean Society for Molecular and Cellular Biology (KSMCB)
• 2025 Next-Generation Scientist Award, S-OIL Science and Culture Foundation
• 2024 Top 100 National R&D Excellence Accomplishment, Ministry of Science and ICT
• 2024 Sasuk Award, Korean Society for Biochemistry and Molecular Biology (KSBMB)
• 2023 Minister of Science and ICT's Citation, Ministry of Science and ICT

Research Interests

• We pioneered a novel concept in cell biology referred to as Adherent-to-Suspension Transition (AST). This innovative paradigm describes how cancer cells reprogram their anchorage dependency to enable transformation into circulating tumor cells (CTCs)

Publications (Max 5)

• Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Non-oncology Drugs. Cancer research. 2026 Mar 2;86(5):1194-1214. (IF: 22.6)
• KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia. Molecular cancer. 2025 Apr 14;24(1):114. (IF: 42.2)
• Noncanonical role of Golgi-associated macrophage TAZ in chronic inflammation and tumorigenesis. Science Advances. 2025 Jan 24;11(4):eadq2395. (IF: 14.1)
• Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia. Molecular Cancer. 2023 Nov 6;22(1):177 (IF: 42.2)
• Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination. Molecular Cancer. 2023 Mar 30;22(1):63 (IF: 42.2)